---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-25-000071"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2025-07-25T23:59:59+00:00"
generated_at: "2026-05-18T01:10:57.271410+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech's VYJUVEK approved in Japan for dystrophic epidermolysis bullosa

## Summary
- Japan's MHLW granted marketing authorization for VYJUVEK on July 24, 2025 for DEB from birth.
- First genetic medicine approved in Japan for DEB; allows home dosing and administration by patients or family.
- Based on Phase 3 data and Japanese open-label extension; all 4 patients achieved full wound closure at 6 months.
- Re-examination period is 10 years; launch expected in Japan by end of 2025.
- Previously approved in US (May 2023) and EU (April 2025).

## SEC filing metadata
- accession: 0001711279-25-000071
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2025-07-25T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000071/0001711279-25-000071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000071/krys-20250725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-25-000071
- JSON: https://secwatch.observer/filing/0001711279-25-000071.json
- Plain text: https://secwatch.observer/filing/0001711279-25-000071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.